TSX:MDNA (Canada)  
Medicenna Therapeutics Corp logo

Medicenna Therapeutics Corp

C$ 1.12 (-3.45%) Sep 23
P/E:
At Loss
P/B:
3.50
Market Cap:
C$ 77.99M ($ 57.34M)
Enterprise V:
C$ 54.62M ($ 40.15M)
Volume:
22.39K
Avg Vol (2M):
92.75K
Also Trade In:
Volume:
22.39K
Market Cap C$:
77.99M
Market Cap $:
57.34M
PE Ratio:
At Loss
Avg Vol (2-Month):
92.75K
Enterprise Value C$:
54.62M
Enterprise Value $:
40.15M
PB Ratio:
3.50
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.89
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 31.48
9-Day RSI 36.3
14-Day RSI 38.72
6-1 Month Momentum % -20.36
12-1 Month Momentum % -57.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.35
Quick Ratio 9.35
Cash Ratio 8.99

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -24.9

Financials (Next Earnings Date:2022-11-11 Est.)

TSX:MDNA's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$) 0
EPS (TTM) (C$) -0.37
Beta -0.03
Volatility % 66.2
14-Day RSI 38.72
14-Day ATR (C$) 0.094894
20-Day SMA (C$) 1.204
12-1 Month Momentum % -57.37
52-Week Range (C$) 0.98 - 3.67
Shares Outstanding (Mil) 69.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Medicenna Therapeutics Corp Filings

Document Form Filing Date
No Filing Data

Medicenna Therapeutics Corp Analysis

Share your research